Tarlatamab治疗小细胞肺癌真实世界CRS与ICANS危险因素及疗效分析
该多中心回顾性研究纳入109例铂类化疗后接受Tarlatamab治疗的广泛期小细胞肺癌患者,分析CRS和ICANS的危险因素及疗效。结果显示高疾病负荷、肝病和基线吸氧与任何级别CRS显著相关,高疾病负荷和中枢神经系统疾病与任何级别ICANS显著相关;ORR为33.7%,中位PFS 3.58个月,中位OS 8.48个月。
要点
- 高疾病负荷、肝病、基线吸氧与任何级别CRS风险显著相关。
- 高疾病负荷及中枢神经系统疾病与任何级别ICANS风险显著相关。
- Tarlatamab在高危人群中毒性可控,ORR 33.7%,中位OS 8.48个月。
核心结论
- 高疾病负荷、肝病和基线吸氧可能增加CRS风险,高疾病负荷和中枢神经系统疾病驱动ICANS风险。
- Tarlatamab在高危患者群体中毒性可控且疗效具有临床意义,支持广泛使用。
- 中枢神经系统疾病患者中,不稳定脑转移与更高的任何级别ICANS相关(p=0.021)。
研究设计与样本
- 多中心回顾性研究,纳入九个癌症中心中铂类化疗后接受Tarlatamab治疗的ES-SCLC患者。
- 共分析109例具有多种高危特征的患者。
- 预设单因素亚组分析包括年龄、体能状态、疾病负荷(>3种转移组织类型)、中枢神经系统疾病、肝病和吸氧等。
主要发现
- 任何级别CRS与高疾病负荷(p=0.002)、肝病(p=0.002)和基线吸氧(p=0.034)显著相关。
- 任何级别ICANS与高疾病负荷(p=0.022)和中枢神经系统疾病史(治疗或未治疗,p=0.015)显著相关。
- 总体ORR为33.7%,中位PFS为3.58个月,中位OS为8.48个月。
- 中枢神经系统特异性ORR为33.3%,包括4例未接受放疗的完全缓解。
临床怎么用
- 对高疾病负荷、肝病或基线吸氧的ES-SCLC患者使用Tarlatamab时,应加强CRS监测。
- 对高疾病负荷或中枢神经系统疾病患者,应关注ICANS风险并做好相应管理。
- Tarlatamab在高危真实世界人群中仍显示可控毒性和临床获益,可考虑用于更广泛患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tarlatamab is the preferred second-line therapy for extensive stage small cell lung cancer (ES-SCLC). However, strict eligibility criteria from trials limit the understanding of safety and efficacy in broader patient populations. METHODS: Patients with ES-SCLC treated with tarlatamab after platinum-based chemotherapy at nine cancer centers were included. Predefined univariate subgroup analyses for cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) included age, performance status, disease burden (>3 metastatic tissue types involved), CNS disease, hepatic disease, and oxygen use among others. Efficacy endpoints were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: A total of 109 patients were analyzed across several high-risk features. Any grade CRS was significantly associated with high disease burden (p = 0.002), hepatic disease (p = 0.002), and baseline oxygen use (p = 0.034). Any grade ICANS was significantly associated with high disease burden (p = 0.022) and a history of treated or untreated CNS disease (p = 0.015). Within the subgroup of patients with CNS disease unstable brain metastasis was associated with higher any grade ICANS (p = 0.021). The ORR was 33.7%, PFS of 3.58 months, and median OS of 8.48 months. CNS-specific ORR was 33.3%, including four complete responses without radiation. CONCLUSION: High disease burden, hepatic disease, and baseline oxygen use may increase CRS risk with high disease burden and CNS disease driving ICANS risk. Tarlatamab demonstrated manageable toxicity with clinically relevant efficacy across high-risk patient populations supporting broad access to this therapy.
引用
- Blocker S, Kim D, Cavalieri CC, et al. Risk factors for CRS and ICANS with tarlatamab in small cell lung cancer and associated efficacy outcomes: Insights from clinical practice. Eur J Cancer. 2026. PMID: 41880872. doi:10.1016/j.ejca.2026.116686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。